November 1st 2021
The FDA has given its approval to Byooviz (ranibizumab-nuna, SB11, Samsung Bioepis Co Inc and Biogen Inc), a biosimilar referencing Lucentis (ranibizumab, Genentech).
Application of Recent Data in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Managed Care Insights and Strategies
View More
(CME Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations
View More
(COPE Credit) Analyzing Novel Tear Stimulating Treatments for Special Populations in Dry Eye Disease
View More
(CME/CNE Credit) Community Practice Connections™: Restoring the Surface Impact of Preservatives and Novel Formulations in First Line Treatments for Dry Eye Disease
View More
(CME/CNE Credit) Analyzing Novel Tear Stimulating Treatments for Special Populations in Dry Eye Disease
View More
(CME Credit) Community Practice Connections™: Improving Management of MGD-Associated Dry Eye Disease—A Look to the Future of Treatment
View More
(COPE Credit) Community Practice Connections™: Improving Management of MGD-Associated Dry Eye Disease—A Look to the Future of Treatment
View More
(COPE Credit) Community Practice Connections™: Restoring the Surface – Impact of Preservatives and Novel Formulations in First Line Treatments for Dry Eye Disease
View More
18th Annual Controversies in Modern Eye Care
May 4, 2024
Register Now!
Headed to ARVO? You’re invited to dinner COPE CE/CME. Or join virtually!
May 6 & 7, 2024
Register Now!
(COPE Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations
View More
(CME Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
2nd Annual IKA Keratoconus Symposium: Front to Back and Everything in Between
May 18-19, 2024
Register Now!
(COPE Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
(CME Credit) Virtual Case Studies™ in Cataract Surgery: Selecting Surgical Techniques and Preventing Intra-Operative Complications
View More
(COPE Credit) Clinical Crossroads: Navigating Neurotrophic Keratitis – The Importance of Avoiding Pitfalls and Ensuring Early Intervention
View More
Neurotrophic Keratitis Management: How Early Intervention Can Make a Difference
View More
(CME Credit) Clinical Crossroads: Navigating Neurotrophic Keratitis – The Importance of Avoiding Pitfalls and Ensuring Early Intervention
View More
17th Annual Controversies in Modern Eye Care
View More
Thyroid Eye Disease: The Masquerading Eye Disorder—A Guide to Collaborative Care and Accurate Diagnosis
View More
(COPE Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
(CME Credit) Community Practice Connections™: Multidisciplinary Perspectives on Saving Sight—The Expanding Role of the Optometrist in Retinal Disease Care
View More
(COPE Credit) Community Practice Connections™: Advances in Geographic Atrophy – Optimizing Diagnosis, Monitoring Progression, and Increasing Communication with Transformative Treatment on the Horizon
View More
(COPE Credit) Community Practice Connections™: Multidisciplinary Perspectives on Saving Sight—The Expanding Role of the Optometrist in Retinal Disease Care
View More
(CME Credit) Community Practice Connections™: Advances in Geographic Atrophy – Optimizing Diagnosis, Monitoring Progression, and Increasing Communication with Transformative Treatment on the Horizon
View More
(CME Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
What’s New in MGD Beyond Heating and Squeezing?
View More
The Ins and Outs of Lubricating Eye Drops
View More
Addressing Healthcare Inequities™ in Glaucoma Management – Understanding Challenges in Segmented Patient Populations (CME Track)
View More
Community Practice Connections™: Expert Perspectives in Diabetic Macular Edema – Considering Pathogenesis & Inflammation in Treatment Selection
View More
Artificial tear protects and lasts to improve dry eye signs
May 15th 2003Clinical practice experience is confirming the results from premarketing clinical trials that showed a new over-the-counter artificial tear product (Systane, Alcon) is a novel approach for modulating the signs and symptoms of dry eye.
Read More
Cyclosporine offers new approach to dry eye treatment
May 15th 2003Maui, HI-FDA approval of Restasis (cyclosporine ophthalmic emulsion, 0.05%, Allergan, Irvine, CA), in December opened a new door for patients with dry eye disease by offering two important "firsts": the drug provides more than palliation of dry eye symptoms, and it targets the inflammation that is the underlying cause of dry eye disease. It may even effect a cure in some patients. The drug became commercially available early last month.
Read More
CA-The FDA approval of gatifloxacin ophthalmic solution 0.3% (Zymar, Allergan) marks a milestone as the first fourth-generation fluoroquinolone to enter the ophthalmic market. The therapy for the treatment of bacterial conjunctivitis caused by susceptible strains of bacteria also has a unique mechanism to prevent development of antibiotic resistance, according to Allergan.
Read More
Allergy agent more potent in inhibition of IL-6, tryptase
May 1st 2003Boston-Ophthalmic solutions of azelastine HCl (Optivar, Asta Medica/Muro Pharmaceutical Inc., Tewksbury, MA) and olopatadine HCl (Patanol, Alcon Laboratories, Fort Worth, TX) both effectively inhibit the activation of normal cultured human mast cells and the release of interleukin-6 (IL-6), tryptase, and histamine. However, azelastine seemed to be substantially more potent for treating ocular allergy when the two drugs were compared in an in vitro study.
Read More
Ocular agent provides prolonged pruritus prophylaxis
May 1st 2003Boston-The mast-cell stabilizer pemirolast potassium 0.1% (Alamast, Santen) is a safe, comfortable, and effective agent for preventing and relieving ocular itching of seasonal allergic conjunctivitis throughout the allergy season, according to a pooled analysis of data from phase III trials.
Read More
ISTA to try again after FDA panel rejects Vitrase
May 1st 2003Irvine, CA-ISTA Pharmaceuticals is regrouping after an FDA advisory committee said the company's tests of ovine hyal-uronidase (Vitrase) failed to demonstrate sufficient statistical evidence to support its efficacy in treating vitreous hemorrhage.
Read More
Anti-VEGF treatment shows promise in preliminary trials
April 15th 2003Boston-Multiple intravitreal injections of rhuFab V2 (Genentech Inc., San Francisco) are well-tolerated and appear to have favorable biologic activity for the treatment of exudative age-related macular degeneration (AMD), said Jeffrey S. Heier, MD, of Ophthalmic Consultants of Boston and the Center for Eye Research, principal investigator for that trial.
Read More
Antibiotic combats acute bacterial conjunctivitis
April 15th 2003Andover, MA-The antibiotic ISV-401 (InSite Vision, Alameda, CA) in development to treat acute bacterial conjunctivitis has achieved a bacterial eradication rate of 85% by the third day of treatment and 90% by 7 to 9 days, according to a phase II clinical trial.
Read More
B&L wins extended range on laser; delays implant application
April 15th 2003Rochester, NY-On the same day Bausch & Lomb celebrated FDA approval of a larger treatment range for its Technolas 217A excimer laser system, it said it would delay a year before asking the FDA to approve its Retisert drug-delivery implant.
Read More
Therapy for retinal arterial macroaneurysms still an open question after 30 years
March 15th 2003This report provides a brief review of macroaneurysms, reviews two recently described applications of investigational tools that may assist in diagnosing a macroaneurysm when it is obscured by hemorrhage, reviews two approaches for the management of subhyaloid hemorrhage arising from a macroaneurysm, and discusses a rationale for the application of photocoagulation when treating selected macroaneurysms.
Read More
Bimanual microphacoemulsification: the next phase?
March 15th 2003Cataract removal by means of phacoemulsification has improved over the last 35 years in small, incremental steps. The sequential introductions of capsulorhexis, foldable IOLs, clear corneal incisions, and topical anesthesia have made small improvements in the safety andefficacy of cataract surgery and as a whole have taken us one giant leap forward.Bimanual phacoemulsification is just another one of these small steps that may ultimately enhance our ability to offer the best surgical procedure to our patients.
Read More